



1-22-03  
DT20 Rec'd PCT/PTO 21 JAN 2003

PCT

CASE 4-31162A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 195226804 US  
Express Mail Label Number

1/21/03  
Date of Deposit

#6  
Dmt  
5-4-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
GATLIN ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP00/09816

FILED: 6 October 2000

U.S. APPLICATION NO: 10/089,971

35 USC §371 DATE: 13 AUGUST 2002

FOR: PHARMACEUTICAL COMPOSITION OF NATEGLINIDE AND  
ANOTHER ANTIDIABETIC AGENT

RECEIVED  
JAN 30 2003  
TECH CENTER 1600/16000

Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report, of which a copy is enclosed herewith. Since these references are of record in the instant PCT application PCT/EP00/09816, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza  
East Hanover, NJ 07936-1080  
(862) 778-7831

  
\_\_\_\_\_  
Gregory D. Ferraro  
Attorney for Applicants  
Reg. No. 36,134

Date:

1/21/03